Understanding the relationship between GSK-3 and Alzheimer's disease: a focus on how GSK-3 can modulate synaptic plasticity processes

被引:1
|
作者
Medina, Miguel [1 ]
Avila, Jesus [1 ,2 ]
机构
[1] Ctr Invest Biomed Red Enfermedades Neurodegenerat, Madrid 28041, Spain
[2] Ctr Biol Mol Severo Ochoa CSIC UAM, Madrid 28049, Spain
关键词
Alzheimer's; dementia; GSK-3; long-term depression; long-term potentiation; memory; neurodegeneration; synaptic plasticity; GLYCOGEN-SYNTHASE KINASE-3; BETA PRECURSOR PROTEIN; LONG-TERM POTENTIATION; TAU-PROTEIN; IN-VIVO; TRANSGENIC MICE; AMYLOID PATHOLOGY; NEURONAL POLARITY; SIGNALING PATHWAY; EXTRACELLULAR TAU;
D O I
10.1586/ERN.13.39
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Originally discovered because of its role in the regulation of glucose metabolism, GSK-3 is now widely recognized as a crucial player in many cellular functions. Control of GSK-3 activity occurs by complex mechanisms that are each dependent upon specific signaling pathways. Furthermore, GSK-3 dysfunction has been linked to a number of pathologies, including Alzheimer's disease (AD). In particular, the involvement of GSK-3 in several key pathophysiological pathways leading to AD and neurodegenerative diseases has placed this enzyme in a central position in this disorder. In this article, the authors will specifically focus on the role of this enzyme as a key regulator of synaptic plasticity and how alterations in the GSK-3 synaptic functions may be a major factor in AD and other neurodegenerative disorders.
引用
收藏
页码:495 / 503
页数:9
相关论文
共 50 条
  • [31] GSK-3β sets Snail's pace
    Schlessinger, K
    Hall, A
    NATURE CELL BIOLOGY, 2004, 6 (10) : 913 - 915
  • [32] GSK-3β sets Snail's pace
    Karni Schlessinger
    Alan Hall
    Nature Cell Biology, 2004, 6 : 913 - 915
  • [33] GSK-3?: An exuberating neuroinflammatory mediator in Parkinson?s disease
    Khan, Sabiya Samim
    Janrao, Sushmita
    Srivastava, Saurabh
    Singh, Shashi Bala
    Vora, Lalitkumar
    Khatri, Dharmendra Kumar
    BIOCHEMICAL PHARMACOLOGY, 2023, 210
  • [34] Inhibition of GSK-3 ameliorates the pathogenesis of Huntington?s disease
    Rippin, Ido
    Bonder, Katherina
    Joseph, Shirley
    Sarsor, Ammar
    Vaks, Lilach
    Eldar-Finkelman, Hagit
    NEUROBIOLOGY OF DISEASE, 2021, 154
  • [35] Dietary regulation of PI3K/AKT/GSK-3β pathway in Alzheimer's disease
    Kitagishi, Yasuko
    Nakanishi, Atsuko
    Ogura, Yasunori
    Matsuda, Satoru
    ALZHEIMERS RESEARCH & THERAPY, 2014, 6 (03):
  • [36] Dietary regulation of PI3K/AKT/GSK-3β pathway in Alzheimer’s disease
    Yasuko Kitagishi
    Atsuko Nakanishi
    Yasunori Ogura
    Satoru Matsuda
    Alzheimer's Research & Therapy, 6
  • [37] Recent Advances in the Discovery of GSK-3 Inhibitors and a Perspective on their Utility for the Treatment of Alzheimer's Disease
    Gentles, Robert G.
    Hu, Shuanghua
    Dubowchik, Gene M.
    ANNUAL REPORTS IN MEDICINAL CHEMISTRY, VOL 44, 2009, 44 : 3 - +
  • [38] Proposition of Potential GSK-3β Inhibitors for the Treatment of Alzheimer's Disease: A Molecular Modeling Study
    Castro, Leandro L.
    Picanco, Leide C. S.
    Silva, Jaderson, V
    Souza, Lucilene R.
    Sousa, Kessia P. A.
    Pinheirol, Abraao A.
    Chaves, Gisele A.
    Teixeira, Hueldem R. C.
    Silva, Guilherme M.
    Taft, Carlton A.
    da Silva, Carlos H. T. de P.
    Hage-Melim, Lorane I. da S.
    CURRENT COMPUTER-AIDED DRUG DESIGN, 2020, 16 (05) : 541 - 554
  • [39] HYPERPHOSPHORYLATION OF TAU BY GSK-3β IN ALZHEIMER'S DISEASE: THE INTERACTION OF Aβ AND SPHINGOLIPID MEDIATORS AS A THERAPEUTIC TARGET
    Jembrek, Maja Jazvinscak
    Babic, Mirjana
    Pivac, Nela
    Hof, Patrick R.
    Simic, Goran
    TRANSLATIONAL NEUROSCIENCE, 2013, 4 (04) : 466 - 476
  • [40] Docking of GSK-3 beta with novel inhibitors, a target protein involved in Alzheimer's disease
    Joshi, Akanksha
    Sharma, Archit
    Kumar, Rajesh
    BIOSCIENCE BIOTECHNOLOGY RESEARCH COMMUNICATIONS, 2018, 11 (02): : 277 - 284